Home » FDA Lifts Clinical Hold on Legend Biotech CAR T-Cell Therapy
FDA Lifts Clinical Hold on Legend Biotech CAR T-Cell Therapy
The FDA has lifted its clinical hold on Legend Biotech’s investigational CAR-T cell therapy, LB1901.
LB1901, which targets malignant CD4+ T-cells, is intended for the treatment of adult patients with relapsed or refractory T-cell lymphoma.
The agency placed the clinical hold in February after a low CD4+ T-cell count was reported for the first patient dosed in the phase 1 study.
The FDA later told Legend that there was insufficient information in the Investigational New Drug application to assess the risks to subjects.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct